February 2021- Volume 17, Issue 2
In this Issue
Commentary
Commentary: How can multiplex immunoassays support vaccine development?
Commentary: How can multiplex immunoassays support vaccine development?
Well-established assay formats that can be used throughout the development continuum are a great benefit to researchers
Editor's Focus
Infectious disease research is a triathlon
Infectious disease research is a triathlon
Dealing with viruses, bacteria and other pathogens requires many approaches
A great leap from clinical trials to clinical practice
A great leap from clinical trials to clinical practice
There is potential for better tying clinical practice to clinical trials, but when will we get there?
Special Reports
Special Report on Natural Products: Mining metabolites
Special Report on Natural Products: Mining metabolites
Rebirth of an industry requires reinvention
Feature
Focus Feature on Vaccines
Focus Feature on Vaccines
mRNA approaches vs. SARS-CoV-2, plus more news of infectious disease and cancer vaccines
Discovery
Rekindling an Old Flame: Targeting tumors with bacteria
Rekindling an Old Flame: Targeting tumors with bacteria
Bacteria have proven to be essential partners in everyday life, but can they also treat cancer?
Scientists map structure of potent antibody against coronavirus
Scientists map structure of potent antibody against coronavirus
Computer-generated images show why immune protein neutralizes SARS-CoV-2
Could Siglec-12 cause cancers to advance?
Could Siglec-12 cause cancers to advance?
People who produce this protein may be at twice the risk for advanced cancer
InveniAI and Kyowa Kirin partner on target discovery
InveniAI and Kyowa Kirin partner on target discovery
The companies have expanded an existing collaboration to find novel targets
Preclinical
Talking about a resolution
Talking about a resolution
Data show that OSE-230 can resolve chronic inflammation
Introducing NGM438
Introducing NGM438
NGM438 is an antagonist antibody that inhibits LAIR1
HCA with 3D models
HCA with 3D models
InSphero-Yokogawa partnership will support drug development research
Out with the old, in with the new
Out with the old, in with the new
New cancer immunotherapy shows promise in treating cancer
Clinical Trials
Ibrexafungerp advances the fight against fungus
Ibrexafungerp advances the fight against fungus
IV compound enters Phase 1, following FDA Priority Review and Fast Track designations for oral formulation
Extending a new option with ExteNET
Extending a new option with ExteNET
Puma reports that neratinib improved CNS outcomes in HER2-positive breast cancer patients
Chimerix acquires Oncoceutics
Chimerix acquires Oncoceutics
Move will expand Chimerix pipeline with late-stage oncology program
Intratumoral therapy
Intratumoral therapy
Plasmid DNA delivery platform looks promising for metastatic melanoma therapy
Diagnostics
AI is put to work on NASH biomarkers
AI is put to work on NASH biomarkers
iBiopsy study shows promise in diagnosing severity of disease in patients
Ingestible capsule offers in-depth diagnostics
Ingestible capsule offers in-depth diagnostics
Progenity presents results on PIL Dx capsule in small intestinal bacterial overgrowth
Tools & Technology
A cHAT about chemistry
A cHAT about chemistry
Rice University chemists detail a greener way to make pharmaceutical intermediates
Drug dissolution solution
Drug dissolution solution
Researchers develop method of assessing time-release drugs
A helping hand from Hemibody
A helping hand from Hemibody
MorphoSys licenses Hemibody technology from Cherry Biolabs in hopes of improving T cell-based therapeutics
Latest Issue
• Volume 17 • Issue 12 • December 2021/January 2022
December 2021/January 2022
December 2021/January 2022 Issue